Drug Trial Radar · NCT01258673
A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy
Last checked: Nov 19, 2026Latest source record: Jan 5, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
263
Actual
Start
Nov 2010
Primary completion
Dec 2011
Sponsor
- Lead sponsor
- Boryung Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Seoul National University Hospital; The Catholic University of Korea; Korea University Guro Hospital; DongGuk University; Seoul National University Bundang Hospital; Samsung Medical Center; Asan Medical Center; Gangnam Severance Hospital; Severance Hospital; Ajou University; Chonbuk National University Hospital; Cheil General Hospital and Women's Healthcare Center; Chonnam National University Hospital; Hanyang University Guri Hospital; Yonsei University; Ilsan-Paik Hospital; SMG-SNU Boramae Medical Center; Kyung Hee University Hospital
- First posted
- Dec 13, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan/Hydrochlorothiazide combination 60/12.5mg\~120/12.5mg in patients with essential hypertension who are not controlled by fimasartan 60mg.
Conditions
- Essential Hypertension
Interventions
Fimasartan/HCTZ combinationDrug
Fimasartan/HCTZ combination 60/12.5mg 120/12.5mg
FimasartanDrug
Fimasartan 60mg, 120mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Diastolic Blood PressureTime frame: 4week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital, Bundang
Sungnam, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.